Key policy priorities in summary
Cervical cancer is one of the most preventable cancers. In Australia, cervical cancer incidence and mortality rates halved between 1991-2002 after the introduction of a national cervical screening program in 1991.[1] However, since then incidence rates in women aged 25-69 have been stable.[2]
It has been established that persistent infection with human papillomavirus (HPV) causes nearly all cervical cancers. This knowledge has led to two important clinical advances: vaccines for primary prevention of cervical cancer, and HPV testing to improve secondary prevention. The introduction of the National HPV Vaccination Program in 2007, delivering the prophylactic vaccine to adolescent girls, is expected to further reduce cervical cancer in Australia. In 2013, the program was extended to include adolescent boys.[3]
Developments in HPV vaccination and screening technologies, along with new evidence on the optimal screening age range and interval led to the need to evaluate the optimal combination and integration of vaccination and screening. A review of Australia’s National Cervical Screening Program led to recommendations to replace Pap tests every two years with HPV testing at an interval of five years and the starting age for screening to be increased from 18 to 25 years. These recommendations were implemented in December 2017.
This chapter discusses the impact of cervical cancer, discusses the policy context in Australia in which both vaccination and screening take place and outlines Cancer Council's policy priorities to reduce the burden of cervical cancer in Australia. Lastly, it discusses the causes, provides information on HPV vaccination and cervical cancer screening.
- Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 2016 Sep;4(9):e609-16 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27470177.
- Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller JT, Garnett GP, et al. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine 2006 Aug 31;24 Suppl 3:S3/251-61 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16950014.
- Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999 Sep;189(1):12-9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/10451482.
- Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012 Nov 15;131(10):2349-59 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22323075.
- Brotherton JML, Tabrizi SN, Phillips S, Pyman J, Cornall AM, Lambie N, et al. Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination. Int J Cancer 2017 Oct 15;141(8):1576-1584 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28677147.
- Giles M, Garland S. Human papillomavirus infection: an old disease, a new vaccine. Aust N Z J Obstet Gynaecol 2006 Jun;46(3):180-5 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16704468.
- International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon, France: IARC; 2013 Dec Available from: http://globocan.iarc.fr/.
- Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008 Jul 15;168(2):123-37 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18483125.
- International Agency for Research on Cancer. IARC handbooks of cancer prevention: volume 10 - cervix cancer screening. Lyon: IARC Press; 2005 Available from: http://www.iarc.fr/en/publications/pdfs-online/prev/handbook10/HANDBOOK10.pdf.
- Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006 May;116(5):1167-73 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16670757.
- Stanley M. Immune responses to human papillomavirus. Vaccine 2006 Mar 30;24 Suppl 1:S16-22 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16219398.
- Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006 Dec 1;119(11):2677-84 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16991121.
- International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, volume 100 B. A review of human carcinogens: Biological agents. Lyon, France: IARC; 2012 Available from: http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-11.pdf.
- Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999 Jul 3;354(9172):20-5 Available from: http://www.ncbi.nlm.nih.gov/pubmed/10406360.
- Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007 Sep 8;370(9590):890-907 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17826171.
- Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003;(31):14-9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12807940.
- Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005 Mar;32 Suppl 1:S16-24 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15753008.
- Proyecto Epidemiológico Guanacaste Group, Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008 Apr 2;100(7):513-7 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18364507.
- Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003 Sep 3;95(17):1336-43 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12953088.
- International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006 Mar 15;118(6):1481-95 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16206285.
- International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006 Sep 1;119(5):1108-24 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16570271.
- International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, volume 100 A. A review of human carcinogens: Pharmaceuticals. Lyon, France: IARC; 2012 Available from: https://monographs.iarc.fr/wp-content/uploads/2018/06/mono100A-19.pdf.
